Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings.

Neuro-degenerative diseases - 1 Jan 2004

Braungart Evelyn, Gerlach Manfred, Riederer Peter, Baumeister Ralf, Hoener Marius C

Abstract excerpt

The neurotoxin MPTP and its active metabolite MPP+ cause Parkinson's disease (PD)-like symptoms in vertebrates by selectively destroying dopaminergic neurons in the substantia nigra. MPTP/MPP+ models have been established in rodents to screen for pharmacologically active compounds. In addition to being costly and time consuming, these animal models are not suitable for large scale testings using compound...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Dopamine Agents
Share to Dopamine Plasma Membrane Transport Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Motor Activity

Share to Parkinson Disease, Secondary

Share to Rotenone

Share to Uncoupling Agents

Source

Identifiers

PMID: 16908987
DOI: 10.1159/000080983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings.PMID 16908987Read ↗

Using a Caenorhabditis elegans Parkinson’s Disease Model to Assess Disease Progression and Therapy EfficiencySemantic proximity Read ↗

Modeling Parkinson's Disease in C. elegans.Semantic proximity Read ↗

Modelling Parkinson's Disease in C. elegans : Strengths and LimitationsSemantic proximity Read ↗

Systematic Review of Caenorhabditis elegans Models for Mechanism Research and Drug Discovery in Parkinson’s DiseaseSemantic proximity Read ↗

Exploring Caenorhabditis elegans as Parkinson’s Disease Model: Neurotoxins and Genetic ImplicationsSemantic proximity Read ↗

Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's diseaseSemantic proximity Read ↗

Caenorhabditis elegans as a model system for target identification and drug screening against neurodegenerative diseasesSemantic proximity Read ↗

Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson’s disease, Alzheimer’s disease and autism spectrum disorderSemantic proximity Read ↗

Traversing a wormhole to combat Parkinson's disease.Semantic proximity Read ↗

Drug discovery: Insights from the invertebrate Caenorhabditis elegansSemantic proximity Read ↗

Towards Understanding Neurodegenerative Diseases: Insights from Caenorhabditis elegansSemantic proximity Read ↗

C. elegans as a powerful model for neurotoxicity assessmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.